Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks

K. Reich^*, R. B. Warren, L. Iversen, L. Puig, I. Pau-Charles, A. Igarashi, M. Ohtsuki, M. Falqués, M. Harmut, S. Rozzo, M. G. Lebwohl, W. Cantrell, A. Blauvelt, D. Thaçi

^*Korrespondierende/r Autor/-in für diese Arbeit